Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors

Leukemia

Volumn 16, Issue 9, 2002, Pages 1589-1595

  Dorsey, J F ^a,b   Cunnick, J M ^a,b   Lanehart, R ^a,b   Huang, M ^a,b   Kraker, A J ^c   Bhalla, K N ^a,b   Jove, R ^a,b   Wu, J ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c PFIZER INC   (United States)

Author keywords

Apoptosis; Bcr Abl; Interleukin 3; Leukemia; Tyrosine kinase inhibitor

Indexed keywords

6 (2,6 DICHLOROPHENYL) 2 (4 FLUORO 3 METHYLANILINO) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ALANINE; ASPARTIC ACID; BCR ABL PROTEIN; CD34 ANTIGEN; DACTINOMYCIN; DIMETHYL SULFOXIDE; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; IMATINIB; INTERLEUKIN 3; KETONE DERIVATIVE; LIPOCORTIN 5; PD 159373; PD 164199; PD 173952; PD 173958; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PYRIDO[2,3 D]PYRIMIDINE DERIVATIVE; TRYPAN BLUE; UNCLASSIFIED DRUG; VALINE;

ANIMAL CELL; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; BINDING ASSAY; CANCER CELL CULTURE; CELL PROTECTION; CELL TRANSFORMATION; CHRONIC MYELOID LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG RESPONSE; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0036736514     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402678     Document Type: Article

References (27)

1. Chronic myeloid leukemia
2. The molecular biology of chronic myeloid leukemia
3. Induction of chronic myelogenous leukemia in mice by the p210bcr/abl gene of the Philadelphia chromosome
4. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
5. Tyrphostin induced growth inhibition: Correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia
6. STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells
7. Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia
8. Activity of a specific inhibitor of the Bcr-Abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
9. Hematologic and cytogenetic responses to Imatinib mesylate in chronic myelogenous leukemia
10. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study
11. Imatinib mesylate-a new oral targeted therapy
12. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
13. Roots of clinical resistance to STI-571 cancer therapy
14. Roots of clinical resistance to STI-571 cancer therapy
15. + acute lymphblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation
16. Bcr-Abl gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukemia to STI571: A prospective study
17. High frequency of point mutations clustered within the adnosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance
18. Marked ploid and BCR-ABL gene amplification in vivo in a patient treated with STI571
19. Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia
20. Biochemical and cellular effects of c-src selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors
21. 2-Substituted aminopyrido[2, 3-d]pyrimidin-7(8H)-ones. Structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity
22. csk
23. Another version of the human insulin receptor kinase domain: Expression, purification, and characterization
24. Characterization of two SHP-2-associated binding proteins and potential substrates in hematopoietic cells
25. Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells
26. Requirement of SHP2 binding to Grb2-associated binder-1 for mitogen-activated protein kinase activation in response to lysophosphatidic acid and epidermal growth factor
27. CGP57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins